Wednesday, September 30, 2015

Clovis Oncology Announces U.S. and E.U. Regulatory Milestones for Rociletinib in the Treatment of Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer

… Advanced EGFR-Mutant T790M+ Non-Small Cell Lung Cancer FDA Grants Priority Review Status … factor receptor (EGFR) non-small cell lung cancer (NSCLC) who have been previously … of advanced mutant EGFR T790M-positive lung cancer. Rociletinib was given Breakthrough Therapy …

No comments:

Post a Comment